Abstract
Objectives
Patients with advanced colorectal cancer (CRC) have multiple concurrent physical and psychological symptoms. This study aimed to explore the relationship between anxiety, depression, and symptom burden in advanced CRC.
Methods
A multicenter cross‐sectional study was conducted in 10 cancer centers from geographically and economically diverse sites in China. A total of 454 patients with advanced CRC completed the Hospital Anxiety and Depression Scale and the MD Anderson Symptom Inventory. Multiple regression analysis was applied to explore the relationship between anxiety, depression and symptom burden.
Results
About one‐third of the patients showed symptoms of anxiety or depression. Patients with anxiety or depression reported significantly higher symptom burden than those without (p < 0.001). Patients with anxiety or depression reported a higher proportion of moderate‐to‐severe (MS) symptom number than those without (p < 0.001). About 52% of the patients with anxiety or depression reported at least three MS symptoms. The prevalence of MS symptoms was ranging from 7.3% (shortness of breath) to 22% (disturbed sleep), and in patients with anxiety or depression was 2–10 times higher than in those without (p < 0.001). Disease stage (β = −2.55, p = 0.003), anxiety (β = 15.33, p < 0.001), and depression (β = 13.63, p < 0.001) were associated with higher symptom burden.
Conclusions
Anxiety and depression in patients with advanced cancer correlated with higher symptom burden. Findings may lead oncology professionals to pay more attention to unrecognized and untreated psychological symptoms in symptom management for advanced cancer patients.
Keywords: advanced cancer, anxiety, colorectal cancer, depression, symptom burden
1. INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer and the second main cause of global cancer‐related mortality, and the incidence and mortality of CRC in China continue to rise higher than the world average rate. 1 CRC patients may experience various physical and psychological symptoms due to their illness or treatment. 2 Patients with CRC are at increased risk for anxiety and depression symptoms or disorders, which decreased quality of life and increased mortality in CRC patients. 3 , 4 About 20%–36.2% of patients with CRC had anxiety symptoms and 19%–30.1% of them had depression symptoms. 5 , 6 Almost 27.5% of advanced CRC patients suffer from anxiety symptoms as well as 28.3% of them suffer from depression symptoms. 7
Most of the previous studies have focused on the relationship between psychological symptoms and one or several physical symptoms in patients with advanced cancer, such as pain, fatigue, and insomnia. 8 , 9 , 10 Few studies have explored the relationship between psychological symptoms and overall symptom burden. To our knowledge, only two studies have examined the relationship between depression symptoms and physical symptom burden. Fitzgerald et al. found that depression symptoms were an independent predictor of physical symptom burden in patients with advanced cancer. 11 Grotmol et al.'s study showed that patients with self‐reported depression disorder reported a twofold higher physical symptom burden compared with those without. 12 Therefore, the relationship between anxiety symptoms and symptom burden in advanced cancer patients is still unclear.
Symptom burden is a significant cause of suffering in advanced cancer patients. 13 Advanced CRC is related to high symptom burden and usually requires hospitalization. 14 Our previous study showed that hospitalized patients with advanced cancer in China have multiple concurrent symptoms, but lack sufficient management. 15 Good symptom management can improve the quality of life of cancer patients, and even prolong their survival. 16 However, despite these benefits, psychological symptoms are often not recognized and treated, highlighting the need for further improvement in care. 17
This study aimed to explore the relationship between anxiety, depression, and symptom burden in advanced CRC. We hypothesized that anxiety and depression symptoms are associated with symptom burden, assuming that patients with anxiety or depression have a higher symptom burden than patients without based on our clinical experience.
2. METHODS
2.1. Study design
This secondary analysis was part of a multicenter cross‐sectional study (Chinese Clinical Trial Registry: ChiCTR1900024957), which was conducted from August 2019 to December 2020. 15 The last CRC patient was enrolled at December 20, 2019. To recruit a representative sample of cancer patients in China, 10 cancer centers were selected from different cities across China: Beijing, Shandong, Fujian, Guangxi, Hubei, Hunan, Henan, Shanxi, Shaanxi, and Sichuan. These cancer centers were selected based on diverse geographical location and level of economic development, which represent diverse socioeconomic status patients.
2.2. Participants
Eligible patients were 18 years of age or older, diagnosed with the advanced CRC, hospitalized for anticancer treatment and/or palliative care, and able to give informed consent. Patients were excluded if they had severe cognitive impairment or communication difficulties or were physically and mentally unable to finish the questionnaire independently. The study was approved by the Institutional Review Board of Peking University Cancer Hospital (2019YJZ34). Written informed consent was obtained from all patients.
2.3. Procedures
Inpatients from 10 cancer centers who met the inclusion criteria were invited to join in the study by their oncologists. Questionnaire were administered to patients by an electronic patient‐reported outcome platform. After patients completed the questionnaires, the data was uploaded to the platform in real time. The system platform converts the data into a standard data schema for data analysis. Our previous studies have shown that using the platform in patients with advanced cancer is time‐saving, energy‐saving, and effective. 18
2.4. Measurements
Demographic variables included age, gender, marital status, and educational status. Clinical characteristics included the disease stage, the disease status, prior chemotherapy, prior radiotherapy, prior surgery, current cancer therapy, current drug therapy for symptoms, and current psychiatric drug therapy. And the Eastern Cooperative Oncology Group performance status, anxiety, depression, and symptom burden were assessed.
The Hospital Anxiety and Depression Scale (HADS) was used to assess anxiety and depression in the past week. 19 It is generally used for patients with psychological symptoms in general hospitals and is also widely used for cancer patients. The Chinese version of the HADS has good reliability and validity. 20 It contains 14 items including two subscales: Anxiety (HADS‐A) and Depression (HADS‐D). Both subscales range from 0 to 21 comprising seven items. A score of 9 or above indicates possible anxiety or depression. 20
The Chinese version of the MD Anderson Symptom Inventory (MDASI‐C) was used to assess cancer‐related symptom burden. 21 Symptom burden is defined as “having at least one moderate‐to‐severe (MS) symptom” among the core symptoms of MDASI. 15 The MDASI‐C has good reliability and validity. 21 It includes 13 symptom items. The MDASI‐C uses an 11‐point numeric scale ranging from 0 (nothing) to 10 (most severe). Scores of 5–6 indicate moderate symptoms, and 7–10 indicate severe symptoms. 21 In the current study, symptom burden was calculated by the summing scores of the 13 symptoms on MDASI‐C.
2.5. Statistical analysis
Continuous variables were reported as the mean ± standard deviation. Categorical variables were reported as percentages (frequency). The cut‐off points of anxiety/depression were 9 as highlighted in the section “Measurements”. Differences in general characteristics, symptom burden and symptoms among patients with or without anxiety and depression were compared by using chi‐square tests for categorical variables, the independent t‐tests for continuous variables, respectively.
Patients were grouped by the number of reported MS symptoms into four groups based on previous studies 15 : no symptom, at least one MS symptom, at least three MS symptoms, and at least five MS symptoms. Differences in the number of MS symptoms among four groups were analyzed using chi‐square tests.
Multiple linear regression model was used to assess the relationship between symptoms burden and anxiety or depression adjusting for the covariates (age and gender) that we defined based on the literature. The variables associated with symptom burden in the univariate analyses were picked for the multiple linear regression analysis, in which symptom burden was used as a continuous variable. The dependent variable of multiple regression model was symptom burden and the independent variables (predictors) were anxiety, depression, and other clinical variables. A two‐sided p < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL, USA).
3. RESULTS
3.1. Participant characteristics
A total of 455 patients with CRC were included in the study. After excluding one patient who did not complete all questionnaires that required for this study, there were 454 patients were entered into the analysis. The sample of 454 patients had a mean age of 56.9 years (standard deviation [SD] = 11.3; range = 19–87 years), and 58.1% were male. Participants were primarily married (95.6%). 53.5% of the patients were in the metastatic disease stage, and 44.3% were in stable disease status. Before hospitalization, 56.4% of patients received chemotherapy, 52.2% patients underwent surgery, and 12.6% received radiotherapy. After hospitalization, 59.7% of patients received anticancer therapy, 40.3% received palliative care, 25.3% received medication for symptom management, and 2.6% received psychiatric medication. The mean scores of symptom burden were 24.82 ± 21.07 (Table 1).
TABLE 1.
Characteristics of the participants.
| Characteristic | N (%) |
|---|---|
| Total, n | 454 |
| Age, mean (SD), years | 56.9 (11.3) |
| Gender | |
| Female | 190 (41.9) |
| Male | 264 (58.1) |
| Marital status | |
| Married | 434 (95.6) |
| Single, divorced or windowed | 20 (4.4) |
| Education | |
| ≤9 years | 227 (50.0) |
| ≥10 years | 227 (50.0) |
| ECOG PS | |
| 0 | 140 (30.8) |
| 1 | 228 (50.2) |
| 2 | 86 (18.9) |
| Disease stage | |
| No evidence of disease | 20 (4.4) |
| Locoregional | 180 (39.6) |
| Locoregional plus metastatic | 11 (2.4) |
| Metastatic | 243 (53.5) |
| Disease status | |
| Complete remission | 16 (3.5) |
| Partial remission | 104 (22.9) |
| Stable disease | 201 (44.3) |
| Progressive disease | 93 (20.5) |
| Unclear | 40 (8.8) |
| Prior chemotherapy | |
| No | 198 (43.6) |
| Yes | 256 (56.4) |
| Prior radiotherapy | |
| No | 397 (87.4) |
| Yes | 57 (12.6) |
| Prior surgery | |
| No | 201 (47.8) |
| Yes | 237 (52.2) |
| Current cancer therapy | |
| Palliative care | 183 (40.3) |
| Anticancer therapy | 271 (59.7) |
| Current drug therapy for symptoms | |
| No | 339 (74.7) |
| Yes | 115 (25.3) |
| Current psychiatric drug | |
| No | 442 (97.4) |
| Yes | 12 (2.6) |
| Anxiety | |
| No | 335 (73.8) |
| Yes | 119 (26.2) |
| Depression | |
| No | 317 (69.8) |
| Yes | 137 (30.2) |
| Anxiety, mean (SD) | 5.60 (4.09) |
| Depression, mean (SD) | 5.92 (4.02) |
| Symptom burden, mean (SD) | 24.82 (21.07) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; SD, standard deviation.
3.2. Anxiety and depression
As shown in Table 1, 119 patients (26.2%) had anxiety (HADS‐A ≥9); 137 patients (30.2%) had depression (HADS‐D ≥9). For total sample, mean scores of anxiety and depression were 5.60 ± 4.09 and 5.92 ± 4.02, respectively (Table 1). There were statistically significant differences between patients with depression or anxiety and those without depression or anxiety in terms of disease stage, disease status, and current cancer therapy (p < 0.05). There is a higher prevalence of anxiety (52.1% vs. 47.9%, p = 0.002), and depression (56.9% vs. 43.1%, p < 0.001) in patients receiving palliative care compared to those receiving anticancer therapy (Table 2).
TABLE 2.
Univariate analysis for anxiety and depression.
| Variables | Anxiety n (%) | p‐Value | Depression n (%) | p‐Value | ||
|---|---|---|---|---|---|---|
| No | Yes | No | Yes | |||
| Total, n | 335 (73.8) | 119 (26.2) | 317 (69.8) | 137 (30.2) | ||
| Age, a years | 57.5 (11.3) | 55.2 (11.4) | 0.059 | 57.2 (11.4) | 56.2 (11.3) | 0.420 |
| Gender | ||||||
| Female | 138 (41.2) | 52 (43.7) | 0.634 | 133 (42.0) | 57 (41.6) | |
| Male | 197 (58.8) | 67 (56.3) | 184 (58.0) | 80 (58.4) | ||
| Marital status | ||||||
| Married | 321 (95.8) | 113 (95.0) | 0.694 | 306 (96.5) | 128 (93.4) | 0.140 |
| Single b | 14 (4.2) | 6 (5.0) | 11 (3.5) | 9 (6.6) | ||
| Education | ||||||
| ≤9 years | 170 (50.7) | 57 (47.9) | 0.594 | 157 (49.5) | 70 (51.1) | 0.759 |
| ≥10 years | 165 (49.3) | 62 (52.1) | 160 (50.5) | 67 (48.9) | ||
| ECOG PS c | ||||||
| 0 and 1 | 277 (82.7) | 91 (76.5) | 0.137 | 264 (83.3) | 104 (75.9) | 0.066 |
| 2 | 58 (17.3) | 28 (23.5) | 53 (16.7) | 33 (24.1) | ||
| Disease stage | ||||||
| No evidence of disease | 13 (3.9) | 7 (5.9) | <0.001 | 13 (4.1) | 7 (5.1) | <0.001 |
| Locoregional | 108 (32.2) | 72 (60.5) | 102 (32.2) | 78 (56.9) | ||
| Locoregional plus metastatic | 7 (2.1) | 4 (3.4) | 8 (2.5) | 3 (2.2) | ||
| Metastatic | 207 (61.8) | 36 (30.3) | 194 (61.2) | 49 (35.8) | ||
| Disease status | ||||||
| Complete remission | 6 (1.8) | 10 (8.4) | <0.001 | 5 (1.6) | 11 (8.0) | <0.001 |
| Partial remission | 60 (17.9) | 44 (37.0) | 57 (18.0) | 47 (34.3) | ||
| Stable disease | 165 (49.3) | 36 (30.3) | 162 (51.1) | 39 (28.5) | ||
| Progressive disease | 71 (21.2) | 22 (18.5) | 62 (19.6) | 31 (22.6) | ||
| Unclear | 33 (9.9) | 7 (5.9) | 31 (9.8) | 9 (6.6) | ||
| Current cancer therapy | ||||||
| Palliative care | 121 (36.1) | 62 (52.1) | 0.002 | 105 (33.1) | 78 (56.9) | <0.001 |
| Anticancer therapy | 214 (63.9) | 57 (47.9) | 212 (66.9) | 59 (43.1) | ||
| Symptom burden a | 18.29 (16.32) | 43.20 (22.10) | <0.001 | 17.85 (16.55) | 40.95 (21.61) | <0.001 |
Note: Significance level at p < 0.05.
Using mean (SD).
Including divorced or windowed.
For Eastern Cooperative Oncology Group performance status.
3.3. Symptom burden
Symptom burden was shown in Tables 2, 3, 4. Symptom burden scores is significantly higher in patients with anxiety (43.2 vs. 18.29, p < 0.001) and depression (40.95 vs. 17.85, p < 0.001) than those without (Table 2).
TABLE 3.
Number of MS symptoms reported in patients with or without anxiety and depression.
| No. of physical MS symptoms | Anxiety n (%) | p‐Value | Depression n (%) | p‐Value | ||
|---|---|---|---|---|---|---|
| No (n =335) | Yes (n =119) | No (n =317) | Yes (n =137) | |||
| 0 | 195 (58.2) | 35 (29.4) | 187 (59.0) | 43 (31.4) | ||
| ≥1 | 140 (41.8) | 84 (70.6) | <0.001 | 130 (41.0) | 94 (68.6) | <0.001 |
| ≥3 | 65 (19.4) | 63 (52.9) | <0.001 | 56 (17.7) | 72 (52.6) | <0.001 |
| ≥5 | 29 (8.7) | 42 (35.3) | <0.001 | 23 (7.3) | 48 (35.0) | <0.001 |
Note: Significance level at p < 0.05.
Abbreviation: MS, moderate‐to‐severe.
TABLE 4.
Prevalence of symptoms in patients with or without anxiety and depression.
| Variables a | Total sample n (%) | Anxiety n (%) | p‐Value | Depression n (%) | p‐Value | ||
|---|---|---|---|---|---|---|---|
| No n = 335 | Yes n = 119 | No n = 317 | Yes n = 137 | ||||
| Fatigue | 97 (21.4) | 50 (14.9) | 47 (39.5) | <0.001 | 48 (15.1) | 49 (35.8) | <0.001 |
| Upset | 73 (16.1) | 30 (9.0) | 43 (36.1) | <0.001 | 25 (7.9) | 48 (35.0) | <0.001 |
| Disturbed sleep | 100 (22.0) | 58 (17.3) | 42 (35.3) | <0.001 | 49 (15.5) | 51 (37.2) | <0.001 |
| Dry mouth | 90 (19.8) | 50 (14.9) | 40 (33.6) | <0.001 | 50 (15.8) | 40 (29.2) | 0.001 |
| Pain | 79 (17.4) | 42 (12.5) | 37 (31.1) | <0.001 | 37 (11.7) | 42 (30.7) | <0.001 |
| Sad | 56 (12.3) | 20 (6.0) | 36 (30.3) | <0.001 | 17 (5.4) | 39 (28.5) | <0.001 |
| Drowsiness | 61 (13.4) | 26 (7.8) | 35 (29.4) | <0.001 | 25 (7.9) | 36 (26.3) | <0.001 |
| Lack of appetite | 76 (16.7) | 46 (13.7) | 30 (25.2) | 0.004 | 38 (12.0) | 38 (27.7) | <0.001 |
| Numbness or tingling | 65 (14.3) | 38 (11.3) | 27 (22.7) | 0.002 | 33 (10.4) | 32 (23.4) | <0.001 |
| Difficulty remembering | 56 (12.3) | 22 (6.6) | 34 (28.6) | <0.001 | 27 (8.5) | 29 (21.2) | <0.001 |
| Nausea | 56 (12.3) | 27 (8.1) | 29 (24.4) | <0.001 | 26 (8.2) | 30 (21.9) | <0.001 |
| Vomiting | 40 (8.8) | 20 (6.0) | 20 (16.8) | <0.001 | 15 (4.7) | 25 (18.2) | <0.001 |
| Shortness of breath | 33 (7.3) | 7 (2.1) | 26 (21.8) | <0.001 | 7 (2.2) | 26 (19.0) | <0.001 |
Note: Significance level at p < 0.05.
For 13 moderate‐to‐severe (≥5) symptoms on the Chinese version of the MD Anderson Symptom Inventory (MDASI‐C).
Compared to patients without anxiety (n = 335), patients with anxiety (n = 119) reported a higher proportion of MS symptom number (p < 0.001), over one symptom (70.6% vs. 41.8%), over three MS symptoms (52.9% vs. 19.4%), and over five MS symptoms (35.3% vs. 8.7%) (Table 3). Compared to the patients without depression (n = 317), patients with depression (n = 137) reported a higher proportion of MS symptom number (p < 0.001), over one MS symptom (68.6% vs. 41.0%), over three MS symptoms (52.6% vs. 17.7%), and over five MS symptoms (35.0% vs. 7.3%) (Table 3).
The prevalence of MS symptoms was ranging from 7.3% (shortness of breath) to 22% (disturbed sleep) in total sample. Disturbed sleep was the most prevalent symptom (22%), followed by fatigue (21.4%), dry mouth (19.8%), pain (17.4%), and lack of appetite (16.7%) among 13 symptoms (Table 4).
In univariate analysis, patients with anxiety reported a higher prevalence of MS symptoms compared to those without anxiety (all p < 0.001), such as fatigue (39.5% vs. 14.9%), upset (36.1% vs. 9.0%), disturbed sleep (35.3% vs. 17.3%), dry mouth (33.6% vs. 14.9%), pain (31.1% vs. 12.5%), and sad (30.3% vs. 6.0%). Patients with depression reported a higher prevalence of MS symptoms compared to those without depression (all p ≤ 0.001), such as disturbed sleep (37.2% vs. 15.5%), fatigue (35.8% vs. 15.1%), upset (35.0% vs. 7.9%), pain (30.7% vs. 11.7%), dry mouth (29.2% vs. 15.8%), and sad (28.5% vs. 5.4%) (Table 4).
3.4. The relationship between anxiety, depression, and symptom burden
Multiple regression analysis showed that symptom burden could be predicted by the disease stage (β = −2.55, p = 0.003), anxiety (β = 15.33, p < 0.001) or depression (β = 13.63, p < 0.001) (Table 5).
TABLE 5.
Multiple regression analyses of the relationship between anxiety, depression, and symptom burden.
| Predictor variable | B | SE | Beta coefficients | p‐Value | 95% CI |
|---|---|---|---|---|---|
| Dependent variable: symptom burden: adjusted R 2 = 0.349; F = 34.220, p < 0.001 | |||||
| Age | 0.03 | 0.07 | 0.02 | 0.700 | −0.11 to 0.17 |
| Gender | 2.34 | 1.65 | 0.06 | 0.157 | −0.90 to 5.58 |
| Disease stage | −2.55 | 0.85 | −0.13 | 0.003 | −4.21 to −0.88 |
| Disease status | 0.26 | 0.89 | 0.01 | 0.772 | −1.50 to 2.01 |
| Current cancer therapy | 1.03 | 1.73 | 0.02 | 0.550 | −2.36 to −4.43 |
| Anxiety | 15.33 | 2.30 | 0.32 | <0.001 | 10.81 to 19.84 |
| Depression | 13.63 | 2.19 | 0.30 | <0.001 | 9.33 to 17.92 |
Note: Significance level at p < 0.05.
Abbreviations: CI, confidence interval; SE, standard error.
4. DISCUSSION
To the best of our knowledge, our study is the first to explore the relationship between anxiety, depression, and symptom burden in patients with advanced CRC. The most important finding of our study was that patients with anxiety or depression reported significantly higher symptom burden than those without.
The present study showed that 26.2% of patients with advanced CRC had symptoms of anxiety, and 30.2% of them had symptoms of depression, consistent with previous studies in advanced CRC 7 and early postoperative CRC. 6 These prevalence rates were significantly higher than those reported in previous studies in CRC survivors. 5 The prevalence of MS symptoms ranged from 7.3% to 22% in patients with advanced CRC similar to previous studies, 22 and in patients with anxiety or depression was 2–10 times higher than those without. For example, the prevalence of symptoms such as fatigue, disturbed sleep, pain, and drowsiness increased more than twice in patients with anxiety and depression. These findings suggest that patients with advanced CRC have high level of anxiety or depression and symptom burden.
Previous studies found cancer patients with depression had a higher symptom burden than non‐depressed patients. 11 , 12 Our study added that patients with advanced cancer and anxiety suffered from a higher symptom burden. Over 50% of patients with anxiety or depression suffered at least three MS symptoms, and nearly a third of patients with anxiety or depression had more than five MS symptoms. In the analysis of specific symptoms, the prevalence of each symptom is higher in patients with anxiety or depression than those without. Our study further explored that anxiety and depression were the predictors of symptom burden on multiple regression analyses. Compared to the study by Fitzgerald et al., 11 our study added a new finding that anxiety is also a predictor of symptom burden in advanced cancer.
Disturbed sleep, fatigue, dry‐mouth, pain and lack of appetite were reported as the top five MS symptoms in patients with advanced CRC, and the prevalence of these symptoms was more than twice higher in patients with anxiety or depression than those without. Cheng et al. found mild to moderate inter‐correlations among insomnia, fatigue, pain, and mood disturbance in cancer patients. 8 It has been suggested that a depression‐pain‐fatigue symptom cluster, 23 , 24 a depression‐sleep‐pain symptom cluster 24 or a sleep‐anxiety‐drowsiness symptom cluster 25 may exist in advanced cancer. However, in addition to the symptoms in these symptom clusters, the prevalence of other physical symptoms such as nausea, vomiting, and shortness of breath were also significantly higher in patients with anxiety or depression than those without. These findings indicate that a collaborative relationship exists between anxiety, depression and physical symptoms in patients with advanced cancer.
Therefore, in clinical practice, the reciprocal effects of anxiety, depression, and symptom burden should be considered, so interventions on either one could impact positively the other one. It means that symptom management could improve patients' depression 26 conversely interventions on anxiety and depression could reduce symptom burden among cancer patients. 27
Unfortunately, there were a huge gap between the need of symptom management and received treatment in patients with advanced cancer. Only 25% of patients were undertaking drug therapy for their symptoms, and only 2.6% of the patients were taking psychiatric medication. It is consistent with the founding of Driessen et al. that the domain of psychological issues is the most unmet care need in advanced cancer patients. 17 The low use of drug therapy for symptoms reveals the current clinical reality that patients with advanced cancer do not receive sufficient symptoms management, but also not get enough attention on their psychological symptoms and not obtain good mental health services. International data also demonstrate that only a small proportion of cancer patients with psychological symptoms receive appropriate treatment. 28 , 29 Inadequate treatment of psychological symptoms may be due to clinicians' insufficient understanding of harm of anxiety or depression and their greater emphasis on physical symptoms rather than psychological symptoms. In addition, current study found the symptom burden were associated with disease stage in advanced cancer; therefore, there should be more attention on symptoms management in palliative care.
Several underlying mechanisms may lead to the fact that anxiety and depression were associated with symptom burden in cancer patients. Anxiety and depression may result in abnormal hyperactivity HPA axis, elevated cortisol levels, release of inflammatory markers, less healthy lifestyles and behavior, which lead to multiple physical symptoms, and even a higher cancer‐specific mortality risk for variety types of cancer including CRC. 30 Some studies suggest that the increase in the proportion of physical symptoms in patients with depression may be due to somatosensory amplification, which indicates that depression can affect the perception and evaluation of physical symptoms through their impact on higher cognitive processing patterns. 11 Although somatosensory amplification is a possible cause for increased proportion, the physical symptoms of patients are actually occurring and painful. Anxiety and depression increase symptom burden and even lead to poor survival, which should attract the attention of all medical personnel providing services for cancer patients.
Our study found that age and gender were not associated with anxiety, depression and symptom burden in patients with advanced CRC. Previous studies showed that the significance of age and sex in the emergence of anxiety or depression in patients with CRC still remains controversial. 4 Lloyd et al. found that older and female patients with CRC were more associated with anxiety and depression. 3 However, Howren et al. showed that younger patients with CRC were more associated with depression compared to older patients. 31 Mols et al. showed that being male was associated with more depressive symptoms. 5 Our findings differed from previous studies because these studies mainly recruit early stage patients, but our study recruited patients with advanced cancer. The finding that age and gender were not related to symptom burden was consistent with previous studies. 32
4.1. Strengths and limitations
The strengths of the current study include the data were recruited from 10 different cancer centers with diverse geographical location and level of economic development across China, that increase the generalizability and representativeness of the results.
This study has several limitations. First, we provided assessments for patients classified as anxious or depressed only according to the HADS. This instrument is widely used and is a valid measurement of anxiety and depression in cancer patients. Second, socioeconomic factors that may interfere (e.g., employment status) were not considered. Third, the associations found in our research do not necessarily mean causation. Fourth, previous psychiatric conditions of patients were not evaluated in our study due to the cross‐sectional design. We also did not investigate the mental health problems of patients before they had cancer, but focused on the relationship between their current psychological state and symptom burden. Finally, the exclusion of outpatient patients represents a selection bias in this study. Future research could include advanced‐stage outpatients to explore the differences in symptom burden between outpatients and inpatients.
5. CONCLUSION AND IMPLICATION
In conclusion, our findings are instructive as this is the first study to examine the association between anxiety, depression, and symptom burden in advanced CRC patients. Anxiety and depression are associated with a significantly higher symptom burden in patients with advanced cancer. The findings may advance our understanding of the psychological symptoms of advanced CRC patients. We emphasize anxiety and depression as important risk factors related to symptom burden in advanced CRC patients despite the limitations of our study. We hope that the findings of this study can enable oncology healthcare professionals to pay more attention to unrecognized and untreated psychological symptoms in advanced cancer patients and timely identify and handle these symptoms through routine screening and referral in future clinical practice. The implementation of psychological services may help to improve symptom management in patients with advanced cancer in oncology and palliative care.
AUTHOR CONTRIBUTIONS
Lili Song: Conceptualization (equal); formal analysis (equal); writing – original draft (equal); writing – review and editing (equal). Zhongge Su: Conceptualization (equal); formal analysis (equal); writing – original draft (equal); writing – review and editing (equal). Ying Pang: Conceptualization (equal). Yi He: Conceptualization (equal). Yuhe Zhou: Data curation (equal). Yu Wang: Investigation (equal). Yongkui Lu: Investigation (equal). Yu Jiang: Investigation (equal). Xinkun Han: Investigation (equal). Lihua Song: Investigation (equal). Liping Wang: Investigation (equal). Zimeng Li: Investigation (equal). Xiaojun Lv: Investigation (equal). Yan Wang: Investigation (equal). Juntao Yao: Investigation (equal). Xiaohong Liu: Investigation (equal). Xiaoyi Zhou: Investigation (equal). Shuangzhi He: Investigation (equal). Yening Zhang: Investigation (equal). Jinjiang Li: Investigation (equal). Bingmei Wang: Investigation (equal). Lili Tang: Conceptualization (equal); funding acquisition (equal); project administration (equal).
FUNDING INFORMATION
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (CI2021A01819); and the Scientific Research and Cultivation Program Foundation of Beijing Hospitals Authority, Beijing, China (No. PX2021045).
CONFLICT OF INTEREST STATEMENT
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
ACKNOWLEDGMENTS
The authors sincerely thank the participants of this study.
Song L, Su Z, He Y, et al. Association between anxiety, depression, and symptom burden in patients with advanced colorectal cancer: A multicenter cross‐sectional study. Cancer Med. 2024;13:e7330. doi: 10.1002/cam4.7330
Lili Song and Zhongge Su have contributed equally to this article.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.
REFERENCES
- 1. Li N, Lu B, Luo C, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America. Cancer Lett. 2021;522:255‐268. [DOI] [PubMed] [Google Scholar]
- 2. Røhrl K, Guren MG, Miaskowski C, Cooper BA, Diep LM, Rustøen T. No differences in symptom burden between colorectal cancer patients receiving curative versus palliative chemotherapy. J Pain Symptom Manag. 2016;52(4):539‐547. [DOI] [PubMed] [Google Scholar]
- 3. Lloyd S, Baraghoshi D, Tao R, et al. Mental health disorders are more common in colorectal cancer survivors and associated with decreased overall survival. J Clin Oncol. 2019;42(4):355‐362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Peng YN, Huang ML, Kao CH. Prevalence of depression and anxiety in colorectal cancer patients: a literature review. Int J Environ Res Public Health. 2019;16(3):411. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Mols F, Schoormans D, de Hingh I, Oerlemans S, Husson O. Symptoms of anxiety and depression among colorectal cancer survivors from the population‐based, longitudinal PROFILES registry: prevalence, predictors, and impact on quality of life. Cancer. 2018;124(12):2621‐2628. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Song L, Han X, Zhang J, Tang L. Body image mediates the effect of stoma status on psychological distress and quality of life in patients with colorectal cancer. Psychooncology. 2020;29(4):796‐802. [DOI] [PubMed] [Google Scholar]
- 7. Husson O, Thong MS, Mols F, Smilde TJ, Creemers GJ, van de Poll‐Franse LV. Information provision and patient reported outcomes in patients with metastasized colorectal cancer: results from the PROFILES registry. J Palliat Med. 2013;16(3):281‐288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Cheng KK, Lee DT. Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol. 2011;78(2):127‐137. [DOI] [PubMed] [Google Scholar]
- 9. Delgado‐Guay M, Yennurajalingam S, Parsons H, Palmer JL, Bruera E. Association between self‐reported sleep disturbance and other symptoms in patients with advanced cancer. J Pain Symptom Manag. 2011;41(5):819‐827. [DOI] [PubMed] [Google Scholar]
- 10. Gibbins J, McCoubrie R, Kendrick AH, Senior‐Smith G, Davies AN, Hanks GW. Sleep‐wake disturbances in patients with advanced cancer and their family carers. J Pain Symptom Manag. 2009;38(6):860‐870. [DOI] [PubMed] [Google Scholar]
- 11. Fitzgerald P, Lo C, Li M, Gagliese L, Zimmermann C, Rodin G. The relationship between depression and physical symptom burden in advanced cancer. BMJ Support Palliat Care. 2015;5(4):381‐388. [DOI] [PubMed] [Google Scholar]
- 12. Grotmol KS, Lie HC, Loge JH, et al. Patients with advanced cancer and depression report a significantly higher symptom burden than non‐depressed patients. Palliat Support Care. 2019;17(2):143‐149. [DOI] [PubMed] [Google Scholar]
- 13. Vogt J, Beyer F, Sistermanns J, et al. Symptom burden and palliative care needs of patients with incurable cancer at diagnosis and during the disease course. Oncologist. 2021;26(6):e1058‐e1065. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Colibaseanu DT, Osagiede O, Spaulding AC, et al. The determinants of palliative care use in patients with colorectal cancer: a National Study. Am J Hosp Palliat Care. 2018;35(10):1295‐1303. [DOI] [PubMed] [Google Scholar]
- 15. He Y, Pang Y, Su Z, et al. Symptom burden, psychological distress, and symptom management status in hospitalized patients with advanced cancer: a multicenter study in China. ESMO Open. 2022;7(6):100595. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non‐small‐cell lung cancer. N Engl J Med. 2010;363:733‐742. [DOI] [PubMed] [Google Scholar]
- 17. Driessen HPA, Busschbach JJV, van der Rijt CCD, et al. Unmet care needs of patients with advanced cancer and their relatives: multicentre observational study. BMJ Support Palliat Care. 2024;14:e1413‐e1421. [DOI] [PubMed] [Google Scholar]
- 18. Tang L, He Y, Pang Y, et al. Implementing symptom management follow‐up using an electronic patient‐reported outcome platform in outpatients with advanced cancer: longitudinal single‐center prospective study. JMIR Form Res. 2022;6(5):e21458. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361‐370. [DOI] [PubMed] [Google Scholar]
- 20. Zheng L, Wang Y, Li H. Application of hospital anxiety and depression scale in general hospital: an analysis in reliability and validity. Shanghai Arch Psychiatry. 2003;15:264‐266. [Google Scholar]
- 21. Wang XS, Wang Y, Guo H, Mendoza TR, Hao XS, Cleeland CS. Chinese version of the M. D. Anderson symptom inventory: validation and application of symptom measurement in cancer patients. Cancer. 2004;101(8):1890‐1901. [DOI] [PubMed] [Google Scholar]
- 22. Cleeland CS, Zhao F, Chang VT, et al. The symptom burden of cancer: evidence for a core set of cancer‐related and treatment‐ related symptoms from the eastern cooperative oncology group symptom outcomes and practice patterns study. Cancer. 2013;119(24):4333‐4340. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Laird BJ, Scott AC, Colvin LA, et al. Pain, depression, and fatigue as a symptom cluster in advanced cancer. J Pain Symptom Manag. 2011;42(1):1‐11. [DOI] [PubMed] [Google Scholar]
- 24. Aktas A, Walsh D, Hauser K, Rybicki L. Should we cluster patients or symptoms? The myth of symptom clusters based on 'depression, insomnia, pain' and 'depression, fatigue, pain'. BMJ Support Palliat Care. 2016;6(2):210‐218. [DOI] [PubMed] [Google Scholar]
- 25. Yennurajalingam S, Williams JL, Chisholm G, Bruera E. Effects of dexamethasone and placebo on symptom clusters in advanced cancer patients: a preliminary report. Oncologist. 2016;21(3):384‐390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Goodwin L, Lee W, Price A, et al. Predictors of non‐remission of depression in a palliative care population. Palliat Med. 2012;26(5):683‐695. [DOI] [PubMed] [Google Scholar]
- 27. Sheinfeld Gorin S, Krebs P, Badr H, et al. Meta‐analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol. 2012;30(5):539‐547. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Walker J, Hansen CH, Martin P, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross‐sectional analysis of routinely collected clinical data. Lancet Psychiatry. 2014;1(5):343‐350. [DOI] [PubMed] [Google Scholar]
- 29. Naser AY, Hameed AN, Mustafa N, et al. Depression and anxiety in patients with cancer: a cross‐sectional study. Front Psychol. 2021;12:585534. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta‐analysis of cohort studies. Mol Psychiatry. 2020;25(7):1487‐1499. [DOI] [PubMed] [Google Scholar]
- 31. Howren A, Sayre EC, Cheng V, et al. Risk of anxiety and depression after diagnosis of young‐onset colorectal cancer: a population‐based cohort study. Curr Oncol. 2022;29(5):3072‐3081. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Fettes L, Bone AE, Etkind SN, Ashford S, Higginson IJ, Maddocks M. Disability in basic activities of daily living is associated with symptom burden in older people with advanced cancer or chronic obstructive pulmonary disease: a secondary data analysis. J Pain Symptom Manag. 2021;61(6):1205‐1214. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.